{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:09:43Z","timestamp":1789852183369,"version":"4.0.1"},"reference-count":32,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adult T-cell leukemia (ATL) develops in a small proportion of individuals infected with human T-cell lymphotrophic virus-1. The leukemia consists of an overabundance of activated T cells, which express CD25 on their cell surfaces. Presently, there is no accepted curative therapy for ATL. Flavopiridol, an inhibitor of cyclin-dependent kinases, has potent antiproliferative effects and antitumor activity. We investigated the therapeutic efficacy of flavopiridol alone and in combination with humanized anti-Tac antibody (HAT), which recognizes CD25, in a murine model of human ATL. The ATL model was established by intraperitoneal injection of MET-1 leukemic cells into nonobese diabetic\/severe combined immunodeficient mice. Either flavopiridol, given 2.5 mg\/kg body weight daily for 5 days, or HAT, given 100 \u03bcg weekly for 4 weeks, inhibited tumor growth as monitored by serum levels of human \u03b2-2-microglobulin (\u03b22\u03bc; P &amp;lt; .01), and prolonged survival of the leukemia-bearing mice (P &amp;lt; .05) as compared with the control group. Combination of the 2 agents dramatically enhanced the antitumor effect, as shown by both \u03b22\u03bc levels and survival of the mice, when compared with those in the flavopiridol or HAT alone group (P &amp;lt; .01). The significantly improved therapeutic efficacy by combining flavopiridol with HAT provides support for a clinical trial in the treatment of ATL.<\/jats:p>","DOI":"10.1182\/blood-2004-05-1709","type":"journal-article","created":{"date-parts":[[2004,9,22]],"date-time":"2004-09-22T01:16:43Z","timestamp":1095815803000},"page":"1231-1236","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":29,"title":["Combination therapy for adult T-cell leukemia\u2013xenografted mice: flavopiridol and anti-CD25 monoclonal antibody"],"prefix":"10.1182","volume":"105","author":[{"given":"Meili","family":"Zhang","sequence":"first","affiliation":[{"name":"From the Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Zhang","sequence":"additional","affiliation":[{"name":"From the Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn K.","family":"Goldman","sequence":"additional","affiliation":[{"name":"From the Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Janik","sequence":"additional","affiliation":[{"name":"From the Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Waldmann","sequence":"additional","affiliation":[{"name":"From the Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021219382305400_REF1","doi-asserted-by":"crossref","unstructured":"Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemialymphoma: a report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79: 428-437.","DOI":"10.1111\/j.1365-2141.1991.tb08051.x"},{"key":"2020021219382305400_REF2","doi-asserted-by":"crossref","unstructured":"Uchiyama T, Broder S, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells, I: production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol. 1981;126: 1393-1397.","DOI":"10.4049\/jimmunol.126.4.1393"},{"key":"2020021219382305400_","doi-asserted-by":"crossref","unstructured":"Waldmann TA, Greene WC, Sarin PS, et al. Functional and phenotypic comparison of human T cell leukemia\/lymphoma virus positive adult T cell leukemia with human T cell leukemia\/lymphoma virus negative Sezary leukemia, and their distinction using anti-Tac: monoclonal antibody identifying the human receptor for T cell growth factor. J Clin Invest. 1984;73: 1711-1718.","DOI":"10.1172\/JCI111379"},{"key":"2020021219382305400_REF4","doi-asserted-by":"crossref","unstructured":"Uchiyama T, Hori T, Tsudo M, et al. Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells. J Clin Invest. 1985;76: 446-453.","DOI":"10.1172\/JCI111992"},{"key":"2020021219382305400_REF5","doi-asserted-by":"crossref","unstructured":"Morris JC, Waldmann TA. Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis. 2000;59(suppl 1): i109-i114.","DOI":"10.1136\/ard.59.suppl_1.i109"},{"key":"2020021219382305400_REF6","doi-asserted-by":"crossref","unstructured":"Waldmann TA, White JD, Carrasquillo JA, et al. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood. 1995;86: 4063-4075.","DOI":"10.1182\/blood.V86.11.4063.bloodjournal86114063"},{"key":"2020021219382305400_REF7","doi-asserted-by":"crossref","unstructured":"Waldmann TA, White JD, Goldman CK, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood. 1993;82: 1701-1712.","DOI":"10.1182\/blood.V82.6.1701.1701"},{"key":"2020021219382305400_REF8","unstructured":"Phillips KE, Herring B, Wilson LA, et al. IL-2Ralpha-directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2\/IL-2Ralpha interaction. Cancer Res. 2000; 60: 6977-6984."},{"key":"2020021219382305400_REF9","doi-asserted-by":"crossref","unstructured":"Zhang M, Yao Z, Garmestani K, et al. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. Blood. 2002;100: 208-216.","DOI":"10.1182\/blood-2002-01-0107"},{"key":"2020021219382305400_REF10","doi-asserted-by":"crossref","unstructured":"Zhang M, Zhang Z, Garmestani K, et al. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia\/lymphoma xenografts. Proc Natl Acad Sci U S A. 2003;100: 1891-1895.","DOI":"10.1073\/pnas.0437788100"},{"key":"2020021219382305400_REF11","doi-asserted-by":"crossref","unstructured":"Zhang Z, Zhang M, Ravetch JV, Goldman C, Waldmann TA. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. Blood. 2003;102: 284-288.","DOI":"10.1182\/blood-2002-11-3601"},{"key":"2020021219382305400_REF12","unstructured":"Zhang Z, Zhang M, Goldman CK, Ravetch JV, Waldmann TA. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res. 2003;63: 6453-6457."},{"key":"2020021219382305400_REF13","unstructured":"Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res. 2002;62: 1083-1086."},{"key":"2020021219382305400_REF14","doi-asserted-by":"crossref","unstructured":"Sedlacek HH. Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol. 2001;38: 139-170.","DOI":"10.1016\/S1040-8428(00)00124-4"},{"key":"2020021219382305400_REF15","doi-asserted-by":"crossref","unstructured":"Parker BW, Kaur G, Nieves-Neira W, et al. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood. 1998;91: 458-465.","DOI":"10.1182\/blood.V91.2.458"},{"key":"2020021219382305400_REF16","doi-asserted-by":"crossref","unstructured":"Schwartz GK, O'Reilly E, Ilson D, et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol. 2002; 20: 2157-2170.","DOI":"10.1200\/JCO.2002.08.080"},{"key":"2020021219382305400_REF17","unstructured":"Arguello F, Alexander M, Sterry JA, et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts. Blood. 1998; 91: 2482-2490."},{"key":"2020021219382305400_REF18","doi-asserted-by":"crossref","unstructured":"Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst. 2000;92: 376-387.","DOI":"10.1093\/jnci\/92.5.376"},{"key":"2020021219382305400_REF19","doi-asserted-by":"crossref","unstructured":"Patel V, Senderowicz AM, Pinto D Jr, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest. 1998;102: 1674-1681.","DOI":"10.1172\/JCI3661"},{"key":"2020021219382305400_REF20","doi-asserted-by":"crossref","unstructured":"Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A. 1989;86: 10029-10033.","DOI":"10.1073\/pnas.86.24.10029"},{"key":"2020021219382305400_REF21","doi-asserted-by":"crossref","unstructured":"Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 2001;1: 118-129.","DOI":"10.1038\/35101072"},{"key":"2020021219382305400_REF22","doi-asserted-by":"crossref","unstructured":"Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84: 2457-2466.","DOI":"10.1182\/blood.V84.8.2457.2457"},{"key":"2020021219382305400_REF23","doi-asserted-by":"crossref","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16: 2825-2833.","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"2020021219382305400_REF24","doi-asserted-by":"crossref","unstructured":"Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17: 2639-2648.","DOI":"10.1200\/JCO.1999.17.9.2639"},{"key":"2020021219382305400_REF25","unstructured":"Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2\/neu overexpressing human breast cancer xenografts. Cancer Res. 1998;58: 2825-2831."},{"key":"2020021219382305400_REF26","doi-asserted-by":"crossref","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344: 783-792.","DOI":"10.1056\/NEJM200103153441101"},{"key":"2020021219382305400_REF27","unstructured":"Yu C, Krystal G, Dent P, Grant S. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Clin Cancer Res. 2002;8: 2976-2984."},{"key":"2020021219382305400_","unstructured":"Bible KC, Kaufmann SH. Cytotoxic synergy between flavopiridol (NSC 649890, L86\u20138275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res. 1997; 57: 3375-3380."},{"key":"2020021219382305400_REF29","unstructured":"Wu K, Wang C, D'Amico M, et al. Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. Mol Cancer Ther. 2002;1: 695-706."},{"key":"2020021219382305400_REF30","doi-asserted-by":"crossref","unstructured":"Zhang M, Zhang Z, Garmestani K, et al. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult T-cell leukemia. Cancer Res. 2004; 64: 5825-5829.","DOI":"10.1158\/0008-5472.CAN-04-1088"},{"key":"2020021219382305400_REF31","doi-asserted-by":"crossref","unstructured":"Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A. 1998;95: 652-656.","DOI":"10.1073\/pnas.95.2.652"},{"key":"2020021219382305400_REF32","doi-asserted-by":"crossref","unstructured":"Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6: 443-446.","DOI":"10.1038\/74704"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/3\/1231\/1706173\/zh800305001231.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/3\/1231\/1706173\/zh800305001231.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T10:24:03Z","timestamp":1682763843000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/105\/3\/1231\/19653\/Combination-therapy-for-adult-Tcell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,1]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,2,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-05-1709","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,1]]}}}